Abbott Laboratories Matches Q3 EPS but Tops Revenue Forecasts as Stock Holds Near $100

By TrendSpider Editor

Abbott's ability to grow revenue by 14.46% year over year is a notable positive given the scale of the business, indicating that organic and product-driven momentum remains intact heading into the final quarter of 2026. However, the stock's positioning, more than $31 above its 52-week low but nearly

Abbott Laboratories Matches Q3 EPS but Tops Revenue Forecasts as Stock Holds Near $100

Key Drivers of the ABT Stock Move

• Main Catalyst: Abbott reported Q3 2026 EPS of $1.42, matching the $1.42 estimate precisely for a 0% surprise, while revenue of $13.01 billion exceeded the $12.99 billion estimate by approximately $26.9 million, a 0.21% positive revenue surprise.
• Bull Case: Revenue growth of 14.46% year over year and earnings growth of 9.23% year over year demonstrate that Abbott is expanding its top and bottom lines at a healthy clip. Beating on revenue, even narrowly, shows the business is generating demand above what analysts modeled.
• Bear Case: The zero percent EPS surprise is unlikely to re-rate the stock higher in the near term. At $100.59, Abbott trades roughly 23.8% below its 52-week high of $132.025, suggesting the stock has yet to recover meaningful ground, and a flat earnings surprise gives investors little reason to aggressively step back in.

Abbott's ability to grow revenue by 14.46% year over year is a notable positive given the scale of the business, indicating that organic and product-driven momentum remains intact heading into the final quarter of 2026. However, the stock's positioning, more than $31 above its 52-week low but nearly $32 below its 52-week high, suggests the market is still working through a broader reset in valuation. The revenue beat, while modest at 0.21%, reinforces that demand trends are holding. Investors will likely focus on forward guidance and segment-level commentary from management to determine whether the 14.46% revenue growth rate is sustainable or whether it benefited from one-time factors in the quarter.

ABT Seasonality

Abbott typically reports Q3 results in late October, and the period has historically been one of stronger revenue quarters given the ramp in diagnostics and medical device demand heading into the fall and winter months. A revenue beat in this seasonal window is consistent with historical patterns for the company.

ABT Relative Performance

Abbott's stock is essentially flat today at +0.08%, reflecting the market's neutral read on an in-line earnings result. With the share price at $100.59 sitting in the lower half of its 52-week range of $81.97 to $132.025, ABT has meaningfully underperformed its own prior highs. The muted price reaction suggests investors are waiting for a stronger earnings catalyst or clearer guidance before committing to a directional move in either direction.